Objective: To test the hypothesis that asymptomatic Alzheimer disease lesions may appear before 50 years of age.
I went to medical school in Santiago, Chile, at the Universidad Cato´lica, where Oscar Marin had been Professor of Neurology from 1961 to 1965. I arrived in 1967. During medical school, although I was supposed to become a surgeon, I fell in love with neurology and devoted as much time as possible to getting experience in neurology and neuroscience.
Only years later did I recognize how much Dr Marin had shaped both the clinical and academic environment in which I had developed my interest. He had either created or heavily influenced the hospital neurology services in which I learned, and he had taught my professors. Dr Jaime Court, my professor of neurology and mentor, had been a student of Dr Marin and co-authored a 1965 paper with him on necrotizing arteries.
After I graduated in 1973, I wished to enter a neurology training program in Santiago. But 1973 was also the year of the military coup in Chile. Things got quite difficult, and my wife, Gloria, and I decided to leave the country.
I wrote to many institutions outside Chile before finding help from a friend of mine, Dr Fernando Miranda, who was doing a neurology residency at the University of Maryland in Baltimore [see Dr Miranda's article in this issue of the journal]. Dr Miranda helped me obtain an internship in internal medicine at the South Baltimore General (now Harborview) Hospital. This internship was a prerequisite for applying for a neurology training program.
We arrived in Baltimore in the last week of June 1974-Gloria, who was pregnant with our son Felipe, and I. On July 1, I began working at South Baltimore General Hospital.
After settling for a few weeks, I decided to visit Dr Marin, who was then on the faculty at the Johns Hopkins University School of Medicine in Baltimore. It was probably late July when I drove to the then Baltimore City Hospitals to meet Dr Marin. I brought a letter of reference from Dr Juan Allamand, a renowned Chilean surgeon who knew him.
I explained my situation to Dr Marin and asked him for advice about seeking training in neurology. He was very warm and receptive. He gave me his perspective on the current neurology training landscape and recommended three or four good East Coast neurology programs where I would be competitive. One of his recommendations was Hahnemann University Hospital in Philadelphia, where I eventually did my neurology residency under the mentorship of Dr Elliott Mancall.
In addition to giving professional advice, Dr Marin invited Gloria and me to visit him at his home. That was when we met the women of the Marin family, Sen˜ora Clara, Clarita, and Andrea (Oscar Jr was away). We saw each other socially several times. Then the Marins asked us if we would house-sit for them in December and January, while they stayed at their apartment in St Denis, Paris. To make a long story short, we were living at the Marins' house when Felipe was born in early January of 1975.
That In retrospect, I appreciate how much Dr Marin influenced my career even before I met him, because he was largely responsible for the thriving neurology environment that so excited me in medical school in Chile. Then, as I moved to the United States, he gave me good advice and strongly supported my professional development.
Dr Marin was a thoughtful mentor who guided my career wisely and at the same time was a wonderful friend.
INTRODUCTION
Alzheimer disease (AD), an age-associated neurodegenerative disease, is the most common cause of dementia in older people. Clinicopathologic studies indicate that by the time patients develop clinical signs of AD, the pathologic hallmarks of beta-amyloid (Ab) plaques and neurofibrillary tangles in the brain are already well established. These observations have led to the widely accepted concept that the cognitive deficits of AD are preceded by a prolonged asymptomatic (Driscoll and Troncoso, 2011; Driscoll et al, 2006) or preclinical (Reiman et al, 1996; Sperling et al, 2011) period during which the pathologic changes progress slowly and silently over many years. This asymptomatic period is of great interest because it may be a critical time when diseasemodifying therapies might be most effective.
The notion of asymptomatic AD emerged from autopsies, first in cross-sectional and then in longitudinal studies (Bennett et al, 2006; Crystal et al, 1988; Davis et al, 1999; Dickson et al, 1992; Miller et al, 1984; Morris and Price, 2001; Price et al, 2009; Sparks et al, 1993; Tomlinson et al, 1968; Troncoso et al, 1996) . These studies demonstrated that neuritic Ab plaques and neurofibrillary tangles are common and frequently meet histopathologic criteria for AD in older people who have documented normal cognition before death (Bennett et al, 2006; Hulette et al, 1998; Katzman et al, 1988; Knopman et al, 2003; Morris and Price, 2001; Price and Morris, 1999; Price et al, 2009; Schmitt et al, 2000; Troncoso et al, 1998) .
More recently, neuroimaging and cerebrospinal fluid (CSF) biomarker studies have also substantiated the concept of asymptomatic AD (Jack et al, 2013) . In vivo imaging of brain Ab by positron emission tomography (PET) scanning (Klunk et al, 2004 ) has revealed Ab deposits in the brains of asymptomatic people not only in old age (Aizenstein et al, 2008; Klunk et al, 2004; Mintun et al, 2006; Resnick et al, 2010; Villemagne et al, 2008) , but also in middle age (Morris et al, 2010) . In asymptomatic carriers of dominant AD mutations, PET with "Pittsburgh compound B" (PiB), a ligand for Ab, has demonstrated Ab deposits as early as 10 to 15 years before the expected age of symptom onset (Bateman et al, 2012) .
Furthermore, an abnormally low concentration of Ab 42 in CSF-a consistent marker of AD brain pathology (Fagan et al, 2014; Fortea et al, 2014; Gustafson et al, 2007; Li et al, 2007; Seppala et al, 2011; Shaw et al, 2009 )-is seen in some normal middle-aged individuals with PiB-negative PET scans. This finding suggests that measurement of Ab 42 in CSF may be the earliest biomarker of AD (Morris et al, 2010) . Morris et al (2010) reported that in 45-to 59-yearolds, the apolipoprotein gene (APOE) genotype correlates with CSF levels of Ab, but not tau. The study also suggested that about 10% to 20% of individuals in this age range might have evidence of AD pathology, depending on their APOE4 status (Corder et al, 1993; Morris et al, 2010; Reiman et al, 2009 ).
In the present study, we tested the hypothesis of a possible extended asymptomatic phase of AD by examining a large series of 154 postmortem brains of people who had died between the ages of 30 and 50 years. We studied the brains for AD lesions, specifically, Ab plaques, neurofibrillary tangles, and tau-positive neurites. We also determined the people's APOE genotypes. Because we did not find Ab in the 30-to 39-year-olds (n = 59), we focused our analysis on the 40-to 50-yearolds (n = 95).
A better understanding of the preclinical stages of AD will give us further insight into the pathogenesis of the disease and guide the timing of potential therapeutic interventions.
METHODS
The neuropathologic studies that we report here are part of a comprehensive program established by the Lieber Institute for Brain Development in Baltimore, Maryland.
We report a total of 154 autopsies performed between September 2012 and June 2014. These autopsies were not consecutive. Our series included a high proportion of subjects with a history of a psychiatric or behavioral abnormality. Lieber Institute staff acquired detailed information about the subjects during life.
All of the autopsies were performed in Baltimore at the Office of the Chief Medical Examiner of the State of Maryland, following protocols authorized by the Institutional Review Board of the Johns Hopkins University School of Medicine and the State of Maryland. Brain examinations and dissections were performed at the Division of Neuropathology of the Johns Hopkins University School of Medicine. Table 1 shows the age, sex, and racial distribution of the 154 people whose brains we studied.
Autopsy Subjects
Staff at the Lieber Institute obtained a comprehensive medical history when consent for brain donation for research was granted. This information included general medical history, history of dementia and psychiatric disorders, medication history, history of alcohol consumption, use and abuse of prescribed analgesics and opiates, and use of illegal drugs. We also obtained information on history of head trauma and participation in contact sports.
The Office of the Chief Medical Examiner provided the cause and manner of death, based on a complete autopsy and toxicology examination.
Neuropathology
Brains were examined externally, weighed, and then cut into coronal slabs. Tissue blocks for histology were dissected, and other tissues were frozen. Tissue blocks for microscopic examination came from the superior frontal gyrus, middle and superior temporal gyri, inferior parietal cortex, occipital cortex, amygdala, hippocampus and entorhinal cortex, midbrain, pons, medulla, and cerebellum. Tissues were fixed in 10% buffered formaldehyde, processed, embedded in paraffin, and cut at 10-mm thickness. All sections were stained with hematoxylin and eosin. Selected sections were silver-stained by the Hirano method (Yamamoto and Hirano, 1986 ) and immunostained with antibodies against ubiquitin (Polyclonal Rabbit Anti-Ubiquitin, Dako North America, Carpinteria, California), phosphorylated monoclonal mouse anti-tau (PHF-1) (a gift of Peter Davies, PhD, Departments of Pathology and Neuroscience, Albert Einstein College of Medicine, Bronx, New York), and mouse monoclonal human against Ab protein (clone: 6E10, Signet Laboratories Inc, Dedham, Massachusetts).
In brains with Ab lesions, we performed single and double immunostains with antibodies for astrocytes (glial fibrillary acidic protein, Dako North America) and microglia (Iba1, Abcam, Cambridge, Massachusetts) to examine potential inflammatory reactions to the Ab deposits.
All microscopic preparations were viewed by conventional light microscopy.
Genotyping
We genotyped all 154 brains for APOE by the method of Hixson and Vernier (1990) .
RESULTS

Ab Lesions
Among the 154 autopsied subjects, we found Ab lesions in the brains of five women and eight men, all of them 40 to 49 years old. In all 13 brains, the lesions were diffuse Ab plaques scattered throughout the neocortex (Figure 1 and Table 2 ). Five of the brains showed Ab lesions limited to the neocortex and not seen in the entorhinal cortex and hippocampus. In eight brains, the Ab plaques extended into the entorhinal cortex and transentorhinal cortices, and four of these eight also showed plaques in the hippocampus ( Table 2) . The severity of Ab deposits was fairly uniform throughout the temporal, frontal, and parietal lobes, but in some brains it appeared lower in the occipital regions. The pattern of Ab deposits was also somewhat variable, ranging from very diffuse blotches of immunoreactivity to more condensed plaques (Figure 1) .
We found vascular Ab in five brains. While all three brains with APOE genotype 4/4 had vascular Ab, only two of 10 brains with APOE3/4 had vascular Ab (Table 2) . We did not notice a correlation between vascular Ab and severity of parenchymal Ab deposits.
None of the 13 brains with Ab deposits showed evidence of astroglial or microglial reactions.
Coexistence of Ab and Tau Lesions
Among the 13 brains with Ab plaques, five had rare and subtle tau lesions limited to the entorhinal cortex and/or hippocampus, with no involvement of the neocortex (Table 2 ). In one brain, we noted rare neurofibrillary tangles in both regions; in the other four, the tau lesions were confined to the entorhinal cortex and consisted of punctate structures in the neuronal perikaryon and subtle neuropil threads similar to lesions in stages 1a and 1b of Braak et al (2011) (Figure 2 ). We saw no tau lesions in the neocortex. The remaining eight brains bearing Ab plaques were free of tau abnormalities in the cerebral cortex.
APOE4 Genotypes
As shown in Table 2 , all 13 individuals whose brain had Ab deposits were 40 to 49 years of age and all carried one or two APOE4 alleles.
For our total series of 154 brains, Table 3 shows the distribution of APOE alleles by age group and race. We found no significant differences in the APOE allele frequency between the subjects 30 to 39 years old and those 40 to 50 years old, or between whites and African Americans. Table 4 shows the APOE genotype distribution in the 95 subjects aged 40 to 50, with and without Ab. All three brains with APOE4/4 had Ab deposits. Of the brains with APOE3/4, 10 (36%) had Ab deposits, but 18 (64%) did not. The brains with other genotypes, including APOE2/4, were free of Ab. Table 5 lists the cause and manner of death for each of the 13 subjects with Ab deposits. As outlined in Table 6 , we did not observe any significant differences in the manner of death between the subjects with and those without Ab deposits. Table 7 compares the medical histories for the 40-to 50-year-olds by their Ab status. The histories were similar except for more heart disease in the Ab-positive group.
DISCUSSION
Our major finding in this study was Ab deposits in 13 of 95 (13.7%) autopsied brains from non-demented individuals between 40 and 50 years of age. The frequency of Ab lesions in this age range was 13.3% in men, 14.3% in women, 15.5% in whites, and 10.4% in African Americans. We did not find Ab deposits in any individual younger than 40.
This last observation is consistent with a study by Braak et al (2011) reporting that Ab deposits started to appear at approximately age 40 and affected 4% of individuals between 40 and 50. Previous studies from our laboratory have also shown that Ab lesions started to appear in the early 40s, and their frequency was 7.8% in 40-to 54-year-olds, without differences between the sexes or races (Sandberg et al, 2001) .
Therefore, it appears that the beginning of the fifth decade is the inflection point for development of Ab deposits and senile plaques, which may be advanced by genetic factors such as Down syndrome (Burger and Vogel, 1973; Cork, 1990; Mann and Esiri, 1989) or amyloid precursor protein and presenilin mutations (Rogaeva, 2002) . The Ab lesions that we saw in this study were diffuse plaques, some perineuronal, and not associated with obvious neuritic or inflammatory components. These plaques were similar to ones that we had reported in the preclinical stages of AD, associated with endosomal and lysosomal abnormalities (Troncoso et al, 1998) . We found the preclinical plaques throughout the neocortex, although less frequently in occipital regions.
Because in the present study we found these lesions only in the subjects aged 40 or older, the lesions likely represent the very early stages of AD pathology. Our belief is reinforced by finding that each of the affected individuals had at least one APOE4 allele.
Notably, only five of the 13 brains with Ab deposits had any tau pathology in the cerebral cortex. The tau lesions were confined to the mesial temporal lobe. None were in the neocortex, where Ab deposition was most severe. This strongly suggests that Ab deposition is the earliest event in AD, preceding the development of local tau lesions and neurofibrillary tangles.
Our observations support the amyloid hypothesis of the pathogenesis of AD, which proposes that abnormal Ab processing, deposition, and clearing are the primordial events in AD, coming before inflammatory changes, tau lesions, and neuronal degeneration (Hardy, 2009; Hardy and Higgins, 1992; Selkoe, 1991) .
Few studies have been done of AD biomarkers in normal young people. We compared our findings to those of Morris et al's (2010) clinical biomarkers study in cognitively normal aging, and we found both differences and similarities. We detected Ab deposits in 13.7% of our subjects 40 to 50 years of age, but Morris et al did not find any Ab deposits on PiB PET scans of subjects aged 45 to 49. This discrepancy suggests that PiB PET scans may not be sensitive enough to detect the very early stages of Ab deposition.
Our results concur with the finding by Morris et al that 18.2% of their subjects had low CSF Ab 42 concentrations. Both studies support the notion that this biomarker is sensitive to very early Ab deposition. Studies of CSF biomarkers in autosomal-dominant AD have associated reduced CSF Ab 42 with Ab plaques as well as with elevated CSF tau in asymptomatic mutation carriers; both markers can be found 10 to 20 years before the estimated age of onset (Fagan et al, 2014) . The APOE4 allele is the major known risk factor for the development of late-onset sporadic AD (Corder et al, 1993) . This effect may be mediated by the increased Ab deposition in the brain and by changes in synaptic repair and plasticity (Verghese et al, 2011) . Furthermore, individuals carrying the APOE4 allele deposit Ab in the brain in a dose-dependent manner during the preclinical stages of the disease (Morris et al, 2010; Reiman et al, 2009 ).
In our sample, all subjects with Ab deposits in the brain carried one or two APOE4 alleles, reaffirming the importance of APOE4 for Ab deposition (Corder et al, 1993) . All three of our subjects who had the E4/E4 genotype had Ab deposits. Although our number of APOE4homozygous subjects was small, the finding that 100% of them had Ab deposits versus only 36% of subjects with APOE3/4 is congruent with the concept of the gene dose effect of APOE (Morris et al, 2010; Reiman et al, 2009 ). Based on our cross-sectional observation, we cannot predict whether these individuals, had they lived longer, would have developed cognitive decline or dementia. However, considering the epidemiologic data on the APOE4 carriers, some probably would have. Importantly, many of the subjects bearing a single APOE4 allele did not show Ab deposits, suggesting that other genetic (Guerreiro et al, 2012 (Guerreiro et al, , 2013 and environmental (Wirth et al, 2014) factors can modulate the risk effect of APOE for Ab deposition and development of AD.
We also note that the frequency of the E4 allele in our African American subjects aged 40 to 50 was 19.6%, consistent with the 19.5% frequency reported in a previous study (Riudavets et al, 2006) .
A major limitation of our study was the nature of the sample. People coming to autopsy in a medical examiner's office do not necessarily represent the population at large, and, in particular, may include a disproportionate number of men and women with a history of substance abuse and/or mental health disorders. This limitation, however, is balanced by the opportunity to examine a large number of brains in a short period of time. Furthermore, the composition of our sample is valuable as it includes a large proportion of African Americans, who have not been well represented in autopsy studies of AD.
In conclusion, our study demonstrates that APOE4 carriers as young as 40 years of age may have asymptomatic or preclinical AD characterized by Ab deposits in the cerebral cortex. Our finding highlights the need to target future AD preventive and therapeutic measures at young people, perhaps triaged on the basis of genetic risk, and the need to develop sensitive biomarkers of AD that can be applied to people in their 40s or even younger.
